EADV spring symposium: Bioalliance Pharma presents Sitavig study results

“This study has shown that Sitavig®, a mucoadhesive buccal tablet, delivers early, very high and prolonged concentrations of acyclovir at the replication site of the herpes virus. Salivary and labial acyclovir concentrations are markedly over those obtained with the other antiviral drugs”

BioAlliance Pharma SA (Euronext Paris - BIO), a Company dedicated to the development of orphan oncology products and supportive care products, has presented the results of the pharmacokinetic and pharmacodynamic study on Sitavig® at the 10th EADV spring symposium (European Academy of Dermatology and Venereology) in Cracow (Poland) on May 24, 2013.

"This study has shown that Sitavig®, a mucoadhesive buccal tablet, delivers early, very high and prolonged concentrations of acyclovir at the replication site of the herpes virus. Salivary and labial acyclovir concentrations are markedly over those obtained with the other antiviral drugs," declares Pierre Attali, COO of BioAlliance Pharma in charge of Strategy and Medical affairs. "This pharmacokinetic profile supported the rationale for a single administration of Sitavig® to treat cold sores as soon as the first signs or symptoms occur."

Together with the marked efficacy on healing time and on pain as well as an excellent safety profile demonstrated in the international phase III trial (LIP study). These results enabled to obtain the registration of Sitavig® in 8 first European countries and in the United States.

In addition to its efficacy, Sitavig® offers a unique discreet and simple formulation with a single application, representing major advantages for patients suffering from recurrent cold sores.

"Sitavig® is the second drug of BioAlliance's Specialty products portofolio to have obtained a market authorization in Europe and the United States. With a market potential of hundreds of millions of dollars, we are searching a partner to commercialize Sitavig® notably in the United States, which would enable to generate significant revenues to the company," declares Aude Michel, Head of Corporate Business Development.

Source BioAlliance Pharma

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
The efficacy of clarithromycin versus levofoxacin-based regimens for H.pylori treatment in naïve patients after the COVID-19 pandemic misuse of antibiotics